JP2015506698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506698A5 JP2015506698A5 JP2014555705A JP2014555705A JP2015506698A5 JP 2015506698 A5 JP2015506698 A5 JP 2015506698A5 JP 2014555705 A JP2014555705 A JP 2014555705A JP 2014555705 A JP2014555705 A JP 2014555705A JP 2015506698 A5 JP2015506698 A5 JP 2015506698A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell
- cells
- inf
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010074328 Interferon-gamma Proteins 0.000 claims description 9
- 102000008070 Interferon-gamma Human genes 0.000 claims description 5
- 229960003130 interferon gamma Drugs 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims 53
- 201000011510 cancer Diseases 0.000 claims 53
- 210000004027 cell Anatomy 0.000 claims 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 201000001441 melanoma Diseases 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 210000004443 dendritic cell Anatomy 0.000 claims 11
- 238000000338 in vitro Methods 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 9
- 230000004987 nonapoptotic effect Effects 0.000 claims 7
- 230000002886 autophagic effect Effects 0.000 claims 6
- 102100037850 Interferon gamma Human genes 0.000 claims 4
- 230000005867 T cell response Effects 0.000 claims 4
- 210000003981 ectoderm Anatomy 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 210000003716 mesoderm Anatomy 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 210000001900 endoderm Anatomy 0.000 claims 3
- 230000003278 mimic effect Effects 0.000 claims 3
- 210000000933 neural crest Anatomy 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 108700012813 7-aminoactinomycin D Proteins 0.000 claims 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 2
- 230000030741 antigen processing and presentation Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 229940030156 cell vaccine Drugs 0.000 claims 2
- 230000036755 cellular response Effects 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 229940115256 melanoma vaccine Drugs 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 claims 1
- 102000000412 Annexin Human genes 0.000 claims 1
- 108050008874 Annexin Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 239000004971 Cross linker Substances 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 108010010995 MART-1 Antigen Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- -1 Mel-2 Proteins 0.000 claims 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 claims 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102000003425 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 230000004900 autophagic degradation Effects 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594304P | 2012-02-02 | 2012-02-02 | |
| US61/594,304 | 2012-02-02 | ||
| PCT/US2013/024123 WO2013116505A1 (en) | 2012-02-02 | 2013-01-31 | Pluripotent germ layer origin antigen presenting cancer vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015506698A JP2015506698A (ja) | 2015-03-05 |
| JP2015506698A5 true JP2015506698A5 (enExample) | 2017-08-24 |
Family
ID=48905824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555705A Pending JP2015506698A (ja) | 2012-02-02 | 2013-01-31 | 多能性胚葉起源抗原を提示する癌ワクチン |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150064217A1 (enExample) |
| EP (1) | EP2809775B1 (enExample) |
| JP (1) | JP2015506698A (enExample) |
| KR (1) | KR20140143361A (enExample) |
| CN (1) | CN104540937A (enExample) |
| AU (1) | AU2013215116A1 (enExample) |
| CA (1) | CA2863653A1 (enExample) |
| GB (1) | GB2512558A (enExample) |
| HK (2) | HK1209455A1 (enExample) |
| IL (1) | IL233928A0 (enExample) |
| NZ (1) | NZ628292A (enExample) |
| SG (1) | SG11201404543UA (enExample) |
| WO (2) | WO2013116541A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599528B (zh) * | 2013-12-04 | 2015-08-05 | 深圳市合一康生物科技股份有限公司 | 人树突状细胞疫苗的制备方法 |
| WO2016056596A1 (ja) | 2014-10-07 | 2016-04-14 | 日本電気株式会社 | Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
| US11291718B2 (en) * | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
| JPWO2018131659A1 (ja) * | 2017-01-11 | 2019-12-12 | 国立研究開発法人国立がん研究センター | 免疫療法剤 |
| IL268744B2 (en) * | 2017-02-17 | 2024-08-01 | Aivita Biomedical Inc | Methods for increasing the immunogenicity of tumors and preparations for autologous immunotherapeutic products against cancer using tumor cells and adapted dendritic cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL140796A0 (en) * | 2001-01-08 | 2002-02-10 | Hadasit Med Res Service | An autologous anti-cancer vaccine |
| BRPI0212545B8 (pt) * | 2001-09-06 | 2021-05-25 | Northwest Biotherapeutics Inc | método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t |
| CN101052709B (zh) * | 2004-10-25 | 2012-06-27 | 贝勒研究院 | 装载热激黑素瘤细胞体的树突细胞 |
| KR101374091B1 (ko) * | 2005-07-29 | 2014-03-17 | 프로비던스 헬스 앤드 서비시즈, 오레곤 | 수포에 담긴 불완전 리보솜 생성물（ＤＲｉｂｂｌｅ） 및 면역 반응을 자극하기 위해 이를 이용하는 방법 |
| WO2008039969A2 (en) * | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| US20090041792A1 (en) * | 2007-07-19 | 2009-02-12 | Istituto Superiore Di Sanita | Dendritic cells, uses therefor, and vaccines and methods comprising the same |
-
2013
- 2013-01-31 CA CA2863653A patent/CA2863653A1/en not_active Abandoned
- 2013-01-31 GB GB1414403.4A patent/GB2512558A/en not_active Withdrawn
- 2013-01-31 JP JP2014555705A patent/JP2015506698A/ja active Pending
- 2013-01-31 SG SG11201404543UA patent/SG11201404543UA/en unknown
- 2013-01-31 NZ NZ628292A patent/NZ628292A/en not_active IP Right Cessation
- 2013-01-31 HK HK15110097.4A patent/HK1209455A1/xx unknown
- 2013-01-31 WO PCT/US2013/024181 patent/WO2013116541A1/en not_active Ceased
- 2013-01-31 CN CN201380017689.2A patent/CN104540937A/zh active Pending
- 2013-01-31 WO PCT/US2013/024123 patent/WO2013116505A1/en not_active Ceased
- 2013-01-31 AU AU2013215116A patent/AU2013215116A1/en not_active Abandoned
- 2013-01-31 KR KR1020147024678A patent/KR20140143361A/ko not_active Ceased
- 2013-01-31 US US14/375,966 patent/US20150064217A1/en not_active Abandoned
- 2013-01-31 EP EP13743673.9A patent/EP2809775B1/en not_active Not-in-force
- 2013-01-31 HK HK15103009.6A patent/HK1202432A1/xx unknown
-
2014
- 2014-08-03 IL IL233928A patent/IL233928A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Church et al. | Tumor‐specific CD 4+ T cells maintain effector and memory tumor‐specific CD 8+ T cells | |
| Melchionda et al. | Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool | |
| ES2601896T3 (es) | Procedimientos de uso de la IL-21 en la inmunoterapia adoptiva y la identificación de antígenos tumorales | |
| Goldinger et al. | Nano‐particle vaccination combined with TLR‐7 and‐9 ligands triggers memory and effector CD 8+ T‐cell responses in melanoma patients | |
| Ugel et al. | Immune tolerance to tumor antigens occurs in a specialized environment of the spleen | |
| Cho et al. | An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2 | |
| Nanjappa et al. | Effects of IL-7 on memory CD8+ T cell homeostasis are influenced by the timing of therapy in mice | |
| Yaddanapudi et al. | Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible? | |
| Galluzzi et al. | Trial Watch: Adoptive cell transfer immunotherapy | |
| Zhang et al. | CD40 ligation reverses T cell tolerance in acute myeloid leukemia | |
| Byrne et al. | Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma | |
| Fenoglio et al. | A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer | |
| Weiss et al. | Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells | |
| Rakshit et al. | Immunotherapeutic efficacy of Mycobacterium indicus pranii in eliciting anti‐tumor T cell responses: Critical roles of IFNγ | |
| JP2014530627A5 (enExample) | ||
| TW202003030A (zh) | 新抗原表位疫苗及免疫刺激組合物及方法 | |
| Thakur et al. | Immunotherapy and immune evasion in prostate cancer | |
| JP2014533938A5 (enExample) | ||
| Koike et al. | Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma | |
| Wirth et al. | Modulating numbers and phenotype of CD8+ T cells in secondary immune responses | |
| Seledtsova et al. | Xenogeneic cell-based vaccine therapy for colorectal cancer: Safety, association of clinical effects with vaccine-induced immune responses | |
| Niavarani et al. | Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer | |
| Danese et al. | The Janus face of CD4+ CD25+ regulatory T cells in cancer and autoimmunity | |
| Byrne et al. | Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma | |
| Chappert et al. | Antigen‐specific Treg impair CD8+ T‐cell priming by blocking early T‐cell expansion |